Literature DB >> 27600388

Is peritoneal dialysis causing a measurable burden of inflammatory and endothelial injury on top of metabolic syndrome?

M Miler1, N Nikolac2, D Segulja3, S Kackov Maslac4, I Celap2, K Altabas5, S Sefer5, A M Simundic6.   

Abstract

PURPOSE: Low-grade chronic inflammation is present in patients on peritoneal dialysis (PD) and in metabolic syndrome (MS). Due to possible greater endothelial changes in dialyzed patients, inflammatory response and oxidative stress are probably stronger in patients on PD. The objective of the study was to investigate possible in between adipokines, inflammatory, endothelial and oxidative stress markers between MS patients and patients on PD.
METHODS: Concentrations of adipokines (leptin, resistin), inflammatory markers [interleukin-6 (IL-6), soluble tumor necrosis factor alpha receptor (sTNF-R), myeloperoxidase (MPO), monocyte chemoattractant protein 1 (MCP-1)] and endothelial markers [soluble intracellular adhesion molecule-1 (sICAM-1), soluble CD40 ligand (sCD40L)] were determined in 55 MS patients and 18 patients on PD, with flow cytometry, and visfatin concentration was measured with ELISA. Routine biochemistry parameters were measured on Beckman Coulter AU2700 analyzer.
RESULTS: Patients on PD have significantly higher concentration of: CRP [6.5 (3.7-12.1) versus 2.6 (1.3-4.0) mg/L, P < 0.001], IL-6 [13.83 (8.48-31.31) versus 2.05 (0.67-4.11) pg/mL, P < 0.001], MCP-1 [2172.28 (1563.84-2922.77) versus 1353.58 (1166.33-1961.70) pg/mL, P = 0.023], sTNF-R [18.25 (12.81-25.22) versus 1.23 (0.89-1.43) ng/mL, P < 0.001] and sICAM-1 [830.03 (599.21-967.02) versus 463.85 (315.25-751.71) ng/mL, P = 0.006] than subjects with MS. MS patients have higher concentrations of MPO [175.47 (120.15-231.67) versus 101.76 (53.55-186.06) ng/mL, P = 0.016] and visfatin [1.5 (0.9-2.3) versus 0.9 (0.6-1.6) ng/mL, P = 0.013].
CONCLUSION: In patients on PD, inflammatory reaction is higher than in patients with MS. On the contrary, patients with MS have stronger oxidative stress response and adipose tissue activity caused probably by the chronic low level of inflammation and underlying metabolic disorders.

Entities:  

Keywords:  Adipokines; Endothelial impairment; Inflammation; Metabolic syndrome; Oxidative stress; Peritoneal dialysis

Mesh:

Substances:

Year:  2016        PMID: 27600388     DOI: 10.1007/s40618-016-0540-7

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

Review 2.  Prognostic value of C-reactive protein for heart disease in dialysis patients.

Authors:  Angela Y-M Wang
Journal:  Curr Opin Investig Drugs       Date:  2005-09

Review 3.  Peritoneal dialysis and inflammation.

Authors:  Marina Souza Silva Velloso; Alba Otoni; Adriano de Paula Sabino; Whocely Victor de Castro; Sérgio Wyton Lima Pinto; Maria Aparecida Silva Marinho; Danyelle Romana Alves Rios
Journal:  Clin Chim Acta       Date:  2013-12-11       Impact factor: 3.786

Review 4.  Adverse effects of systemic glucose absorption with peritoneal dialysis: how good is the evidence?

Authors:  Rajnish Mehrotra; Ian H de Boer; Jonathan Himmelfarb
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

5.  Preliminary observations on the association between serum IL-6 and hydration status and cardiovascular risk in patients treated with peritoneal dialysis.

Authors:  Dorota Sikorska; Krzysztof Pawlaczyk; Magdalena Roszak; Natasza Czepulis; Andrzej Oko; Marek Karczewski; Andrzej Breborowicz; Janusz Witowski
Journal:  Cytokine       Date:  2016-06-29       Impact factor: 3.861

6.  Inflammation as a Link between Obesity and Metabolic Syndrome.

Authors:  Faloia Emanuela; Michetti Grazia; De Robertis Marco; Luconi Maria Paola; Furlani Giorgio; Boscaro Marco
Journal:  J Nutr Metab       Date:  2012-03-01

Review 7.  Chronic kidney disease influences multiple systems: describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease.

Authors:  Patrick S Tucker; Aaron T Scanlan; Vincent J Dalbo
Journal:  Oxid Med Cell Longev       Date:  2015-03-15       Impact factor: 6.543

8.  Oxidative status imbalance in patients with metabolic syndrome: role of the myeloperoxidase/hydrogen peroxide axis.

Authors:  Lucas José Sá da Fonseca; Valéria Nunes-Souza; Glaucevane da Silva Guedes; Glauber Schettino-Silva; Marco Antônio Mota-Gomes; Luíza Antas Rabelo
Journal:  Oxid Med Cell Longev       Date:  2014-10-15       Impact factor: 6.543

9.  Association of Adiponectin with High-Sensitivity C-Reactive Protein and Clinical Outcomes in Peritoneal Dialysis Patients: A 3.5-Year Follow-Up Study.

Authors:  Chun-Wu Tung; Yung-Chien Hsu; Ya-Hsueh Shih; Chun-Liang Lin
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

10.  Associations between the duration of dialysis, endotoxemia, monocyte chemoattractant protein-1, and the effects of a short-dwell exchange in patients requiring continuous ambulatory peritoneal dialysis.

Authors:  Chia-Lin Wu; Hung-Ming Wu; Ping-Fang Chiu; Hung-Hsiang Liou; Chirn-Bin Chang; Der-Cherng Tarng; Chia-Chu Chang
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

View more
  2 in total

Review 1.  New-Onset Diabetes Mellitus in Peritoneal Dialysis and Hemodialysis Patients: Frequency, Risk Factors, and Prognosis-A Review.

Authors:  Rajashri Yarragudi; Alois Gessl; Andreas Vychytil
Journal:  Ther Apher Dial       Date:  2019-04-23       Impact factor: 1.762

2.  Clinical characterization and prognostic implications of metabolic syndrome in patients undergoing peritoneal dialysis at a Chinese center.

Authors:  Rui-Ning Zhang; Hui-Fang Hao; Wei Zhang; Qing Li; Li-Jie Ren; Lan Jia; Fang Wei; Hai-Yan Chen; Zhe Wang; Xue-Qing Bi; Hai-Yan Pang; Ai-Li Jiang; Yi-Liang Wei
Journal:  J Int Med Res       Date:  2019-09-18       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.